Literature DB >> 18195683

High incidence of graft failure in unrelated cord blood transplantation using a reduced-intensity preparative regimen consisting of fludarabine and melphalan.

H Narimatsu, M Watanabe, A Kohno, K Sugimoto, Y Kuwatsuka, T Uchida, M Murata, K Miyamura, Y Morishita.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18195683     DOI： 10.1038/sj.bmt.1705978

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  11 in total

1.  Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant.

Authors:  Stefan O Ciurea; Rima M Saliba; Nelson Hamerschlak; Amado J Karduss Aurueta; Roland Bassett; Marcelo Fernandez-Vina; Demetrios Petropoulos; Laura L Worth; Ka Wah Chan; Daniel R Couriel; Gabriela Rondon; Manish Sharma; Muzaffar Qazilbash; Roy B Jones; Partow Kebriaei; John McMannis; Chitra M Hosing; Yago Nieto; Richard E Champlin; Elizabeth J Shpall; Marcos de Lima
Journal:  Leuk Lymphoma       Date:  2012-01-03

2.  Feasibility of umbilical cord blood transplantation with a myeloablative, reduced toxicity-conditioning regimen.

Authors:  M Nishimoto; H Nakamae; M Nakamae; A Hirose; K Hagihara; H Koh; T Nakane; Y Terada; M Hino
Journal:  Bone Marrow Transplant       Date:  2014-04-07       Impact factor: 5.483

3.  Increase of bone marrow macrophages and CD8+ T lymphocytes predict graft failure after allogeneic bone marrow or cord blood transplantation.

Authors:  N Kawashima; S Terakura; S Nishiwaki; D Koyama; Y Ozawa; M Ito; K Miyamura
Journal:  Bone Marrow Transplant       Date:  2017-04-03       Impact factor: 5.483

4.  Improved survival after single-unit cord blood transplantation using fludarabine and melphalan-based reduced-intensity conditioning for malignant lymphoma: impact of melphalan dose and graft-versus-host disease prophylaxis with mycophenolate mofetil.

Authors:  Kazuki Sakatoku; Sung-Won Kim; Hiroshi Okamura; Minoru Kanaya; Koji Kato; Satoshi Yamasaki; Naoyuki Uchida; Hikaru Kobayashi; Takahiro Fukuda; Nobuyuki Takayama; Jun Ishikawa; Hideyuki Nakazawa; Masatoshi Sakurai; Takashi Ikeda; Tadakazu Kondo; Satoshi Yoshioka; Toshihiro Miyamoto; Takafumi Kimura; Tatsuo Ichinohe; Yoshiko Atsuta; Eisei Kondo
Journal:  Ann Hematol       Date:  2022-10-05       Impact factor: 4.030

5.  Double umbilical cord blood transplantation in patients with hematologic malignancies using a reduced-intensity preparative regimen without antithymocyte globulin.

Authors:  F Ostronoff; F Milano; T Gooley; J A Gutman; P McSweeney; F B Petersen; B M Sandmaier; R Storb; C Delaney
Journal:  Bone Marrow Transplant       Date:  2012-12-17       Impact factor: 5.483

6.  A novel reduced-intensity umbilical cord blood transplantation using a recombinant G-CSF combined with high-dose Ara-C for active myeloid malignancies.

Authors:  M Gotoh; S Yoshizawa; S Katagiri; T Suguro; M Asano; T Kitahara; D Akahane; S Okabe; T Tauchi; Y Ito; K Ohyashiki
Journal:  Bone Marrow Transplant       Date:  2014-04-14       Impact factor: 5.483

7.  Immune Reactions following Cord Blood Transplantations in Adults.

Authors:  Hiroto Narimatsu
Journal:  Stem Cells Int       Date:  2011-06-05       Impact factor: 5.443

8.  Prospective study of one- vs two-unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies.

Authors:  T L Kindwall-Keller; Y Hegerfeldt; H J Meyerson; S Margevicius; P Fu; W van Heeckeren; H M Lazarus; B W Cooper; S L Gerson; P Barr; W W Tse; C Curtis; L R Fanning; R J Creger; J M Carlson-Barko; M J Laughlin
Journal:  Bone Marrow Transplant       Date:  2011-10-17       Impact factor: 5.483

9.  Phase II study of intrabone single unit cord blood transplantation for hematological malignancies.

Authors:  Makoto Murata; Yoshinobu Maeda; Masayoshi Masuko; Yasushi Onishi; Tomoyuki Endo; Seitaro Terakura; Yuichi Ishikawa; Chisako Iriyama; Yoko Ushijima; Tatsunori Goto; Nobuharu Fujii; Mitsune Tanimoto; Hironori Kobayashi; Yasuhiko Shibasaki; Noriko Fukuhara; Yoshihiro Inamoto; Ritsuro Suzuki; Yoshihisa Kodera; Tadashi Matsushita; Hitoshi Kiyoi; Tomoki Naoe; Tetsuya Nishida
Journal:  Cancer Sci       Date:  2017-06-29       Impact factor: 6.716

10.  Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study.

Authors:  Zimin Sun; Huilan Liu; Chenhui Luo; Liangquan Geng; Changcheng Zheng; Baolin Tang; Xiaoyu Zhu; Juan Tong; Xingbing Wang; Kaiyang Ding; Xiang Wan; Lei Zhang; Wen Yao; Kaiding Song; Xuhan Zhang; Yue Wu; Huizhi Yang; Yongsheng Han; Xin Liu; Weibo Zhu; Jingsheng Wu; Zuyi Wang
Journal:  Int J Cancer       Date:  2018-03-12       Impact factor: 7.396
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.